All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Saturday 16th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S803 was presented by Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US, on the efficacy and safety of atezolizumab plus R-CHOP.
The results of the interim analysis were presented of a phase I/II study on the use of atezolizumab, an anti-PD-L1 antibody, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) (NCT02596971). The primary endpoint was complete response (CR) by PET-CT and safety. The secondary endpoints were objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) by investigator assessment and MRD.
Dr Younes concluded that at the interim analysis, R-CHOP with atezolizumab showed encouraging activity in patients with previously untreated DLBCL with a manageable safety profile.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox